Objective: Continuous temperature monitoring in high-risk patients can enable healthcare providers to remotely track patients’ temperatures, promptly detect fevers and timely intervene to improve clinical outcomes. We evaluated if a novel wearable, continuous temperature monitor (Verily Patch) can reliably estimate body temperature and early detect fevers in an outpatient setting in patients at a high risk of febrile neutropenia (FN) who recently underwent chemotherapy and autologous stem cell transplantation (ASCT). Methods: 86 patients at a high risk for FN were prospectively enrolled at Mayo Clinic, MN. Patients wore the device in their axilla region for 7 days post ASCT and recorded self-measured oral temperatures every 3 hours. Patients were also followed using clinical standard-of-care procedures with daily oral temperature assessment. The clinic- and patient-assessed oral temperatures were used to develop and evaluate Verily Patch’s body temperature and early fever detection algorithms using a K-fold cross-validation approach. Results: The Verily Patch reliably measured body temperatures with an error of 0.35 ± 0.88°F in comparison to clinic- and patient-assessed oral temperatures. The sensitivity and specificity of the patch in detecting clinic-assessed fever episodes was 90.2% and 87.8%. The patch detected 14.3 times the number of clinic-assessed fever episodes with a median lead time of 4.3 hours. Conclusion: Patient self-monitoring of temperature and fever incidents suffers from low accuracy and is impractical for extended periods of time. Continuous temperature monitoring by a wearable device (such as Verily Patch) has the potential to overcome these challenges resulting in better patient clinical outcomes and more cost-effective care.

中文翻译：

---

用于连续温度监测和发烧检测的新型可穿戴设备


目的：对高危患者进行持续体温监测，使医疗保健提供者能够远程跟踪患者体温，及时发现发烧情况并及时干预，以改善临床结果。我们评估了新型可穿戴式连续温度监测器（Verily Patch）是否能够可靠地估计体温并在门诊环境中早期检测最近接受化疗和自体干细胞移植（ASCT）的发热性中性粒细胞减少症（FN）高风险患者的发烧情况）。方法：明尼苏达州 Mayo Clinic 前瞻性招募了 86 名 FN 高风险患者。 ASCT 后 7 天，患者在腋窝区域佩戴该设备，并每 3 小时记录一次自我测量的口腔温度。还使用临床标准护理程序对患者进行随访，并进行每日口腔温度评估。临床和患者评估的口腔温度用于使用 K 折交叉验证方法开发和评估 Verily Patch 的体温和早期发烧检测算法。结果：Verily Patch 能够可靠地测量体温，与临床和患者评估的口腔温度相比，误差为 0.35 ± 0.88°F。该贴片检测临床评估发热发作的敏感性和特异性分别为 90.2% 和 87.8%。该贴片检测到的发烧次数是临床评估发烧次数的 14.3 倍，中位时间为 4.3 小时。结论：患者自我监测体温和发热事件的准确性较低，且无法长期使用。可穿戴设备（例如 Verily Patch）的连续​​温度监测有可能克服这些挑战，从而实现更好的患者临床结果和更具成本效益的护理。